Bleeding risk in female patients undergoing intravesical injection of onabotulinumtoxinA for overactive bladder: a Danish retrospective cohort study

Keyphrases

• Retrospective Cohort Study 100%
• Female Patients 100%
• Botulinum Neurotoxin (BoNT) 100%
• Bleeding Risk 100%
• OnabotulinumtoxinA 100%
• Intravesical Injection 100%
• Overactive Bladder 100%
• Antithrombotic Therapy 44%
• Bleeding 22%
• Perioperative Management 22%
• Low Risk 11%
• University Hospital 11%
• Botox 11%
• Obstetrics 11%
• Anticoagulant Therapy 11%
• Patient Management 11%
• Hematuria 11%
• Detrusor 11%
• Medical Journals 11%
• Antiplatelet Therapy 11%
• Data Extraction 11%
• Herlev 11%
• Clinical Recommendations 11%
• Retrospective Cohort 11%
• Intravesical 11%
• Microscopic Hematuria 11%
• January 2015 11%
• Electronic Health 11%
• Ration Level 11%
• Department of Gynecology 11%

Medicine and Dentistry

• Botulinum Toxin A 100%
• Bleeding 100%
• Overactive Bladder 100%
• Retrospective Cohort Study 100%
• Antithrombotic Therapy 100%
• Intravesical Drug Administration 100%
• Hematuria 50%
• Gynecology 25%
• Obstetrics 25%
• Antithrombotic 25%
• Antiplatelet 25%
• Detrusor 25%
• Promethazine 25%